F3 Platform Biologics, Inc

F3 brings existing radioprotective and cytoprotective science to market in new and meaningful ways. Our first application coming to market, AmiGuard CT™, is a lower dose regimen of the FDA approved drug Amifostine—a solution that helps prevent radiation-induced genomic damage and instability (RIGDI), such as from the radiation present in CT scans. RIGDI is a precursor to carcinogenesis. We hold a worldwide exclusive license and patents for a broad spectrum of applications and markets for Amifostine and other compounds. We have a history of proven success in biotechnologies that help people while generating value for investors and partners.